Boston Scientific Corporation (NYSE:BSX) Shares Sold by First American Trust FSB

First American Trust FSB cut its stake in Boston Scientific Corporation (NYSE:BSX) by 0.4% in the first quarter, HoldingsChannel reports. The fund owned 107,065 shares of the medical equipment provider’s stock after selling 412 shares during the period. Boston Scientific accounts for approximately 1.0% of First American Trust FSB’s investment portfolio, making the stock its 27th largest holding. First American Trust FSB’s holdings in Boston Scientific were worth $10,801,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG increased its position in shares of Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock valued at $6,529,000 after buying an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE increased its position in shares of Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider’s stock valued at $2,189,000 after buying an additional 1,439 shares in the last quarter. DRW Securities LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $233,000. Finally, Rockefeller Capital Management L.P. increased its position in shares of Boston Scientific by 7.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 148,074 shares of the medical equipment provider’s stock valued at $13,191,000 after buying an additional 10,110 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $103.22 on Friday. Boston Scientific Corporation has a 52 week low of $75.00 and a 52 week high of $108.94. The business’s fifty day simple moving average is $103.54 and its 200-day simple moving average is $102.07. The firm has a market cap of $152.95 billion, a PE ratio of 61.44, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66. The company has a quick ratio of 0.88, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the company earned $0.62 EPS. Boston Scientific’s revenue was up 22.8% on a year-over-year basis. Equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Citigroup restated a “buy” rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. BTIG Research restated a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, April 29th. Needham & Company LLC reiterated a “buy” rating and set a $115.00 price target on shares of Boston Scientific in a research report on Wednesday, May 28th. Finally, Raymond James Financial boosted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Two research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $117.50.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. The trade was a 10.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock worth $35,976,603 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.